$0.37
11.90% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US86664M2061
Symbol
PBLA
Sector
Industry

Panbela Therapeutics Inc Stock price

$0.42
+0.00 0.00% 1M
+0.06 16.12% 6M
+0.04 10.53% YTD
-0.81 65.85% 1Y
-46,799.58 100.00% 3Y
-4.56 91.57% 5Y
-4.56 91.57% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.01 1.20%
ISIN
US86664M2061
Symbol
PBLA
Sector
Industry

Key metrics

Market capitalization $2.04m
Enterprise Value $8.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.04m
Free Cash Flow (TTM) Free Cash Flow $-15.57m
Cash position $140.00k
EPS (TTM) EPS $-32.52
P/E forward 0.00
Short interest 3.07%
Show more

Is Panbela Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Panbela Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Panbela Therapeutics Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Panbela Therapeutics Inc:

Hold
100%

Financial data from Panbela Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.35 4.35
25% 25%
-
- Research and Development Expense 25 25
37% 37%
-
-29 -29
22% 22%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
22% 22%
-
Net Profit -28 -28
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Panbela Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Panbela Therapeutics Inc Stock News

Neutral
Seeking Alpha
4 months ago
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2024 Earnings Call. At this time, all participants are on a listen-only mode and a question-and-an...
Neutral
GlobeNewsWire
4 months ago
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p....

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Head office United States
CEO Jennifer Simpson
Employees 8
Founded 2011
Website www.panbela.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today